Literature DB >> 17317105

Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: role of oxidative stress pathway genes.

B K Thelma, Arun K Tiwari, Smita N Deshpande, Bernard Lerer, Vishwajit L Nimgaonkar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17317105      PMCID： PMC2435191          DOI： 10.1016/j.schres.2006.12.019

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  11 in total

Review 1.  Oxidative mechanisms and tardive dyskinesia.

Authors:  James B Lohr; Ronald Kuczenski; Alexander B Niculescu
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Clinical implications of pharmacogenomics for tardive dyskinesia.

Authors:  D J Müller; T Shinkai; V De Luca; J L Kennedy
Journal:  Pharmacogenomics J       Date:  2004       Impact factor: 3.550

3.  II. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India.

Authors:  Smita N Deshpande; Panchami G Varma; Prachi Semwal; Atmakuri R Rao; Triptish Bhatia; Vishwajit L Nimgaonkar; Bernard Lerer; B K Thelma
Journal:  Psychiatr Genet       Date:  2005-09       Impact factor: 2.458

4.  A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia.

Authors:  Ofer Sadan; Merav Bahat-Stromza; Yossi Gilgun-Sherki; Daphne Atlas; Eldad Melamed; Daniel Offen
Journal:  Clin Neuropharmacol       Date:  2005 Nov-Dec       Impact factor: 1.592

5.  Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism.

Authors:  A K Tiwari; S N Deshpande; B Lerer; V L Nimgaonkar; B K Thelma
Journal:  Pharmacogenomics J       Date:  2006-09-12       Impact factor: 3.550

6.  Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms.

Authors:  Arun K Tiwari; Smita N Deshpande; A R Rao; Triptish Bhatia; Bernard Lerer; Vishwajit L Nimgaonkar; B K Thelma
Journal:  Schizophr Res       Date:  2005-06-01       Impact factor: 4.939

7.  Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms.

Authors:  Vibhuti Srivastava; Panchami G Varma; Suman Prasad; Prachi Semwal; Vishwajit L Nimgaonkar; Bernard Lerer; Smita N Deshpande; Thelma BK
Journal:  Pharmacogenet Genomics       Date:  2006-02       Impact factor: 2.089

8.  Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism.

Authors:  A K Tiwari; S N Deshpande; A R Rao; T Bhatia; S R Mukit; V Shriharsh; B Lerer; V L Nimagaonkar; B K Thelma
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

Review 9.  Endothelial nitric oxide synthase in vascular disease: from marvel to menace.

Authors:  Ulrich Förstermann; Thomas Münzel
Journal:  Circulation       Date:  2006-04-04       Impact factor: 29.690

10.  Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group.

Authors:  L A Adler; J Rotrosen; R Edson; P Lavori; J Lohr; R Hitzemann; D Raisch; M Caligiuri; K Tracy
Journal:  Arch Gen Psychiatry       Date:  1999-09
View more
  6 in total

1.  Association study of MiRSNPs with schizophrenia, tardive dyskinesia and cognition.

Authors:  Jibin John; Triptish Bhatia; Prachi Kukshal; Puneet Chandna; Vishwajit L Nimgaonkar; Smita N Deshpande; B K Thelma
Journal:  Schizophr Res       Date:  2016-04-19       Impact factor: 4.939

2.  Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls.

Authors:  Xiang Y Zhang; Da C Chen; Mei H Xiu; Fu D Yang; Yunlong Tan; Xingguang Luo; Lingjun Zuo; Therese A Kosten; Thomas R Kosten
Journal:  Schizophr Bull       Date:  2013-04-15       Impact factor: 9.306

3.  Oxidative stress in schizophrenia.

Authors:  Marija Bošković; Tomaž Vovk; Blanka Kores Plesničar; Iztok Grabnar
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

Review 4.  Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders.

Authors:  Florence Cf Chang; Victor Sc Fung
Journal:  Pharmgenomics Pers Med       Date:  2014-10-13

5.  Long non-coding RNA-associated competing endogenous RNA axes in the olfactory epithelium in schizophrenia: a bioinformatics analysis.

Authors:  Hani Sabaie; Marziyeh Mazaheri Moghaddam; Madiheh Mazaheri Moghaddam; Nazanin Amirinejad; Mohammad Reza Asadi; Yousef Daneshmandpour; Bashdar Mahmud Hussen; Mohammad Taheri; Maryam Rezazadeh
Journal:  Sci Rep       Date:  2021-12-30       Impact factor: 4.379

6.  Meta-Analyses of Manganese Superoxide Dismutase Activity, Gene Ala-9Val Polymorphism, and the Risk of Schizophrenia.

Authors:  Dong-Fang Wang; Bing Cao; Mei-Yan Xu; Ya-Qiong Liu; Lai-Lai Yan; Rong Liu; Jing-Yu Wang; Qing-Bin Lu
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.